Based on the Oversight and Investigations hearing, political will in Congress seems slim to cut back the 340B program — without a clearer view of how hospitals are using the funds first.
House subcommittee lands on transparency for 340B reform Read More »
La iluminación industrial ha experimentado una revolución en los últimos años gracias a la adopción de la tecnología LED. Estos avances no solo mejoran la eficiencia energética y reducen costes, sino que también ofrecen soluciones m&a …
The biggest conferences of the year dominated news this week: the American Society of Clinical Oncology annual meeting and the BIO International Convention.
The ABCs of Biopharma This Week: ASCO, BIO and Cancer Read More »
Marcus Schabacker called for more upfront regulations and postmarket monitoring to better understand how AI features affect patient care.
Stronger oversight of AI needed in medical devices, ECRI CEO says Read More »
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 2:00 p.m. ET in Miami, FL.
Mallinckrodt plc, a global specialty pharmaceutical company, announced the presentation of three posters on TERLIVAZ® for injection in patients with hepatorenal syndrome with rapid reduction in kidney function1 at the 2024 European Association for the Study of the Liver Congress taking place in Milan, Italy from June 5-8, 2024.
Virion Therapeutics, LLC announced positive immunologic and continued safety and tolerability data, from the first-ever human study of its novel, first-in-class, checkpoint modifier immunotherapy, VRON-0200, for HBV functional cure, presented by Professor Ed Gane, M.D., from the University of Auckland, as a late breaker at the EASL Congress 2024 in Milan, Italy.
Las enfermedades parasitarias representan una amenaza significativa para la salud pública en todo el mundo. Estas enfermedades, causadas por organismos como protozoos, helmintos y ectoparásitos, afectan a millones de personas, especialmente en regiones tropicales y subtropicales. &nbs …
Ascentage Pharma announced that it has released updated clinical data of olverembatinib, a third-generation tyrosine kinase inhibitor, in patients with TKI-resistant succinate dehydrogenase -deficient gastrointestinal stromal tumor, in an oral report at the 60th American Society of Clinical Oncology Annual Meeting taking place in Chicago, IL.
International medical imaging IT and cybersecurity company Sectra reports that all operating areas are growing, and the Group’s sales for the fourth quarter surpassed earlier record-breaking levels.
